

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
6.1	11.08.2025	595280-00021	Date of first issue: 04.04.2016

---

**Section 1: Identification**

Product name : Ertugliflozin (< 2%) / Sitagliptin Formulation

**Manufacturer or supplier's details**

Company : MSD

Address : 33 Whakatiki Street - Private Bag 908  
Upper Hutt - New Zealand

Telephone : 0800 800 543

Emergency telephone number : 0800 764 766 (0800 POISON) 0800 243 622 (0800 CHEMCALL)

E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

---

**Section 2: Hazard identification****GHS Classification**

Skin corrosion/irritation : Category 2

Serious eye damage/eye irritation : Category 2

Skin sensitisation : Category 1

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Kidney, Stomach, Prostate)

Hazardous to the aquatic environment - chronic hazard : Category 3

**GHS label elements**

Hazard pictograms :



Signal word : Warning

Hazard statements : H315 Causes skin irritation.  
H317 May cause an allergic skin reaction.

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version 6.1	Revision Date: 11.08.2025	SDS Number: 595280-00021	Date of last issue: 14.04.2025 Date of first issue: 04.04.2016
----------------	------------------------------	-----------------------------	---

H319 Causes serious eye irritation.  
H373 May cause damage to organs (Kidney, Stomach, Prostate) through prolonged or repeated exposure if swallowed.  
H412 Harmful to aquatic life with long lasting effects.

**Precautionary statements**

:

**Prevention:**

P261 Avoid breathing dust.  
P264 Wash skin thoroughly after handling.  
P272 Contaminated work clothing should not be allowed out of the workplace.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ eye protection/ face protection.

**Response:**

P302 + P352 IF ON SKIN: Wash with plenty of water.  
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.  
P314 Get medical advice/ attention if you feel unwell.  
P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.  
P337 + P313 If eye irritation persists: Get medical advice/ attention.  
P362 + P364 Take off contaminated clothing and wash it before reuse.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

May form explosive dust-air mixture during processing, handling or other means.

**Section 3: Composition/information on ingredients**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Sitagliptin Phosphate	654671-77-9	>= 30 -< 50
Cellulose	9004-34-6	>= 30 -< 50
Ertugliflozin	1210344-83-4	>= 1 -< 3
Magnesium stearate	557-04-0	>= 1 -< 10
Propyl 3,4,5-trihydroxybenzoate	121-79-9	>= 0.25 -< 1

**Section 4: First-aid measures**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical

## Ertugliflozin (< 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
6.1	11.08.2025	595280-00021	Date of first issue: 04.04.2016

---

	advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	: In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: Causes skin irritation. May cause an allergic skin reaction. Causes serious eye irritation. May cause damage to organs through prolonged or repeated exposure if swallowed.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

---

### Section 5: Fire-fighting measures

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Metal oxides Oxides of phosphorus
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment	: In the event of fire, wear self-contained breathing apparatus.

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version 6.1	Revision Date: 11.08.2025	SDS Number: 595280-00021	Date of last issue: 14.04.2025 Date of first issue: 04.04.2016
----------------	------------------------------	-----------------------------	---

for firefighters

Use personal protective equipment.

**Section 6: Accidental release measures**

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**Section 7: Handling and storage**

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
Do not breathe dust.  
Do not swallow.  
Do not get in eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye

## Ertugliflozin (&lt; 2%) / Sitagliptin Formulation

Version 6.1	Revision Date: 11.08.2025	SDS Number: 595280-00021	Date of last issue: 14.04.2025 Date of first issue: 04.04.2016
----------------	------------------------------	-----------------------------	---

flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Contaminated work clothing should not be allowed out of the workplace.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage : Keep in properly labelled containers.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

## Section 8: Exposure controls/personal protection

## Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Sitagliptin Phosphate	654671-77-9	TWA	0.6 mg/m <sup>3</sup> (OEB 2)	Internal
Cellulose	9004-34-6	WES-TWA	10 mg/m <sup>3</sup>	NZ OEL
		TWA	10 mg/m <sup>3</sup>	ACGIH
Ertugliflozin	1210344-83-4	TWA	10 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	100 µg/100 cm <sup>2</sup>	Internal
Magnesium stearate	557-04-0	WES-TWA	10 mg/m <sup>3</sup>	NZ OEL
		TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
Minimize open handling.

**Personal protective equipment**

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the rec-

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
6.1	11.08.2025	595280-00021	Date of first issue: 04.04.2016

---

Filter type	: Recommended guidelines, use respiratory protection.
Hand protection	: Particulates type
Material	: Chemical-resistant gloves
Remarks	: Consider double gloving.
Eye protection	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

---

**Section 9: Physical and chemical properties**

Appearance	: powder
Colour	: No data available
Odour	: No data available
Odour Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: Not applicable
Evaporation rate	: Not applicable
Flammability (solid, gas)	: May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapour pressure	: Not applicable

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
6.1	11.08.2025	595280-00021	Date of first issue: 04.04.2016

---

Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics		
Particle size	:	No data available

---

**Section 10: Stability and reactivity**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

**Section 11: Toxicological information**

Exposure routes	:	Inhalation Skin contact Ingestion Eye contact
-----------------	---	--

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
6.1	11.08.2025	595280-00021	Date of first issue: 04.04.2016

---

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

**Components:****Sitagliptin Phosphate:**

Acute oral toxicity : LD50 (Rat): > 3,000 mg/kg  
LD50 (Mouse): 3,000 mg/kg

**Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

**Ertugliflozin:**

Acute oral toxicity : LD50 (Rat): 500 mg/kg  
Acute inhalation toxicity : Remarks: No data available  
Acute dermal toxicity : Remarks: No data available

**Magnesium stearate:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity  
Remarks: Based on data from similar materials  
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
Remarks: Based on data from similar materials

**Propyl 3,4,5-trihydroxybenzoate:**

Acute oral toxicity : LD50 (Mouse): 1,700 mg/kg  
Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 402  
Assessment: The substance or mixture has no acute dermal toxicity



**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
6.1	11.08.2025	595280-00021	Date of first issue: 04.04.2016

---

**Skin corrosion/irritation**

Causes skin irritation.

**Components:****Sitagliptin Phosphate:**

Species	:	Rabbit
Method	:	Draize Test
Result	:	No skin irritation

**Ertugliflozin:**

Result	:	Corrosive
--------	---	-----------

**Magnesium stearate:**

Species	:	Rabbit
Result	:	No skin irritation
Remarks	:	Based on data from similar materials

**Propyl 3,4,5-trihydroxybenzoate:**

Species	:	reconstructed human epidermis (RhE)
Method	:	OECD Test Guideline 439
Result	:	No skin irritation

**Serious eye damage/eye irritation**

Causes serious eye irritation.

**Components:****Sitagliptin Phosphate:**

Species	:	Rabbit
Result	:	Irritating to eyes.
Method	:	Draize Test

**Ertugliflozin:**

Result	:	Severe irritation
--------	---	-------------------

**Magnesium stearate:**

Species	:	Rabbit
Result	:	No eye irritation
Remarks	:	Based on data from similar materials

**Propyl 3,4,5-trihydroxybenzoate:**

Species	:	Rabbit
Result	:	Irreversible effects on the eye
Method	:	OECD Test Guideline 405

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
6.1	11.08.2025	595280-00021	Date of first issue: 04.04.2016

---

**Respiratory or skin sensitisation****Skin sensitisation**

May cause an allergic skin reaction.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****Sitagliptin Phosphate:**

Test Type	: Local lymph node assay (LLNA)
Species	: Mouse
Method	: OECD Test Guideline 429
Result	: Not a skin sensitizer.

**Ertugliflozin:**

Test Type	: Local lymph node assay (LLNA)
Result	: Not a skin sensitizer.

**Magnesium stearate:**

Test Type	: Maximisation Test
Exposure routes	: Skin contact
Species	: Guinea pig
Method	: OECD Test Guideline 406
Result	: negative
Remarks	: Based on data from similar materials

**Propyl 3,4,5-trihydroxybenzoate:**

Test Type	: Local lymph node assay (LLNA)
Exposure routes	: Skin contact
Species	: Mouse
Result	: positive

Assessment	: Probability or evidence of skin sensitisation in humans
------------	---

**Chronic toxicity****Germ cell mutagenicity**

Not classified based on available information.

**Components:****Sitagliptin Phosphate:**

Genotoxicity in vitro	: Test Type: Ames test Result: negative
-----------------------	--

	Test Type: Chromosome aberration test in vitro Test system: Chinese hamster ovary cells Result: negative
--	--

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
6.1	11.08.2025	595280-00021	Date of first issue: 04.04.2016

---

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Test system: rat hepatocytes  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Application Route: Oral  
Result: negative

**Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

**Ertugliflozin:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Rat  
Result: negative

**Magnesium stearate:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

**Propyl 3,4,5-trihydroxybenzoate:**

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
6.1	11.08.2025	595280-00021	Date of first issue: 04.04.2016

---

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: positive

Test Type: Chromosome aberration test in vitro  
Result: positive

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Result: negative

Test Type: In vitro sister chromatid exchange assay in mammalian cells  
Result: positive

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****Sitagliptin Phosphate:**

Species : Mouse  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

Species : Rat  
Application Route : oral (drinking water)  
Exposure time : 2 Years  
Result : positive  
Target Organs : Liver  
Remarks : Significant toxicity observed in testing

Carcinogenicity - Assessment : Weight of evidence does not support classification as a carcinogen

**Cellulose:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
6.1	11.08.2025	595280-00021	Date of first issue: 04.04.2016

---

**Ertugliflozin:**

Species	: Mouse
Application Route	: Oral
Exposure time	: 2 Years
Result	: negative

Species	: Rat
Application Route	: Oral
Exposure time	: 2 Years
Result	: negative

Carcinogenicity - Assessment	: Weight of evidence does not support classification as a carcinogen
------------------------------	--

**Propyl 3,4,5-trihydroxybenzoate:**

Species	: Rat
Application Route	: Ingestion
Exposure time	: 103 weeks
Result	: negative

**Reproductive toxicity**

Not classified based on available information.

**Components:****Sitagliptin Phosphate:**

Effects on fertility	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Oral Fertility: NOAEL Parent: 1,000 mg/kg body weight Result: Animal testing did not show any effects on fertility.
----------------------	--

Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Oral Teratogenicity: LOAEL: 250 mg/kg body weight Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects
-------------------------------	--

Test Type: Embryo-foetal development Species: Rabbit Teratogenicity: NOAEL: 125 mg/kg body weight Result: No teratogenic effects
---

**Cellulose:**

Effects on fertility	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
----------------------	---

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue:
6.1	11.08.2025	595280-00021	14.04.2025
			Date of first issue: 04.04.2016

---

Effects on foetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Ertugliflozin:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 250 mg/kg body weight  
Remarks: Maternal toxicity observed.  
No significant adverse effects were reported

Test Type: Fertility/early embryonic development  
Species: Rabbit  
Application Route: Oral  
Fertility: NOAEL: 200 mg/kg body weight  
Remarks: No significant adverse effects were reported

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 50 mg/kg body weight  
Remarks: Adverse developmental effects were observed

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: 250 mg/kg body weight  
Remarks: No significant adverse effects were reported

**Magnesium stearate:**

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

**Propyl 3,4,5-trihydroxybenzoate:**

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
6.1	11.08.2025	595280-00021	Date of first issue: 04.04.2016

---

Result: negative

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

May cause damage to organs (Kidney, Stomach, Prostate) through prolonged or repeated exposure if swallowed.

**Components:****Ertugliflozin:**

Exposure routes : Oral  
Target Organs : Kidney, Stomach, Prostate  
Assessment : May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Sitagliptin Phosphate:**

Species : Mouse  
NOAEL : 500 mg/kg  
LOAEL : 1,000 mg/kg  
Application Route : Oral  
Exposure time : > 2 yr  
Target Organs : Kidney

Species : Rat  
NOAEL : 500 mg/kg  
LOAEL : 1,000 mg/kg  
Application Route : Oral  
Exposure time : 14 Weeks  
Target Organs : Liver, Kidney, Heart, Teeth

Species : Dog  
NOAEL : 10 mg/kg  
LOAEL : 50 mg/kg  
Application Route : Oral  
Exposure time : 53 Weeks  
Target Organs : Central nervous system  
Symptoms : Loss of balance  
Remarks : The mechanism or mode of action may not be relevant in humans.

Species : Dog

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
6.1	11.08.2025	595280-00021	Date of first issue: 04.04.2016

---

NOAEL : 2 mg/kg  
LOAEL : 10 mg/kg  
Application Route : Oral  
Exposure time : 27 Weeks  
Target Organs : Skeletal muscle, Central nervous system  
Symptoms : Loss of balance  
Remarks : The mechanism or mode of action may not be relevant in humans.

Species : Monkey  
NOAEL : 100 mg/kg  
Application Route : Oral  
Exposure time : 14 Weeks  
Remarks : No significant adverse effects were reported

**Cellulose:**

Species : Rat  
NOAEL :  $\geq 9,000$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

**Ertugliflozin:**

Species : Rat  
LOAEL : 500 mg/kg  
Application Route : Oral  
Exposure time : 30 d

Species : Rat  
LOAEL : 250 mg/kg  
Application Route : Oral  
Exposure time : 30 d  
Target Organs : Kidney

Species : Rat  
LOAEL : 25 mg/kg  
Application Route : Oral  
Exposure time : 180 d  
Target Organs : Kidney, Bone, Stomach

Species : Rat  
LOAEL : 25 mg/kg  
Exposure time : 90 d  
Target Organs : Kidney, Gastrointestinal tract, Prostate

Species : Dog  
NOAEL : 150 mg/kg  
Application Route : Oral  
Exposure time : 270 d  
Remarks : No significant adverse effects were reported

Species : Mouse



**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
6.1	11.08.2025	595280-00021	Date of first issue: 04.04.2016

---

NOAEL : 100 mg/kg  
Application Route : Oral  
Exposure time : 90 d  
Remarks : No significant adverse effects were reported

Species : Mouse  
NOAEL : 100 mg/kg  
Application Route : Oral  
Exposure time : 28 d  
Target Organs : Bone  
Remarks : No significant adverse effects were reported

**Magnesium stearate:**

Species : Rat  
NOAEL : > 100 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days  
Remarks : Based on data from similar materials

**Propyl 3,4,5-trihydroxybenzoate:**

Species : Rat  
NOAEL : 135 mg/kg  
Application Route : Ingestion  
Exposure time : 13 Weeks

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Sitagliptin Phosphate:**

Inhalation : Symptoms: upper respiratory tract infection, pharyngitis, Headache  
Ingestion : Symptoms: upper respiratory tract infection, nasopharyngitis, Headache, Nausea, Abdominal pain, Diarrhoea

**Ertugliflozin:**

Ingestion : Symptoms: The most common side effects are:, Headache, constipation, Diarrhoea, Nausea, urinary tract infection, muscle pain, upper respiratory tract infection

---

**Section 12: Ecological information****Ecotoxicity****Components:****Sitagliptin Phosphate:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l

## Ertugliflozin (&lt; 2%) / Sitagliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
6.1	11.08.2025	595280-00021	Date of first issue: 04.04.2016

---

Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 60 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 39 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 2.2 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 9.2 mg/l  
Exposure time: 33 d  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 9.8 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 150 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC: 150 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition

**Cellulose:**

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

**Ertugliflozin:**

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 77 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 50 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 1 mg/l  
Exposure time: 32 d

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue:
6.1	11.08.2025	595280-00021	14.04.2025
			Date of first issue: 04.04.2016

---

Method: OECD Test Guideline 210  
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 2.14 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211  
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50: > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC: 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

**Magnesium stearate:**

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
Exposure time: 48 h  
Method: DIN 38412  
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l  
Exposure time: 47 h  
Test substance: Water Accommodated Fraction  
Method: Directive 67/548/EEC, Annex V, C.2.  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l  
Exposure time: 16 h  
Test substance: Water Accommodated Fraction  
Remarks: Based on data from similar materials

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue:
6.1	11.08.2025	595280-00021	14.04.2025
			Date of first issue: 04.04.2016

---

**Propyl 3,4,5-trihydroxybenzoate:**

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 19.6 mg/l  
Exposure time: 48 h  
Test substance: Neutralised product  
Method: OECD Test Guideline 202  
Remarks: The test was conducted according to guideline

Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): 0.22 mg/l  
Exposure time: 72 h  
Test substance: Neutralised product  
Method: OECD Test Guideline 201  
Remarks: The test was conducted according to guideline

EC10 (Pseudokirchneriella subcapitata (green algae)): 0.096 mg/l  
Exposure time: 72 h  
Test substance: Neutralised product  
Method: OECD Test Guideline 201  
Remarks: The test was conducted according to guideline

M-Factor (Acute aquatic toxicity) : 1  
M-Factor (Chronic aquatic toxicity) : 1  
Toxicity to microorganisms : EC50 (activated sludge): 636 mg/l  
Exposure time: 3 h  
Method: OECD Test Guideline 209

**Persistence and degradability****Components:****Sitagliptin Phosphate:**

Biodegradability : Result: not rapidly degradable  
Biodegradation: 39.7 %  
Exposure time: 28 d  
Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(401 d)  
Method: OECD Test Guideline 111

**Cellulose:**

Biodegradability : Result: Readily biodegradable.

**Ertugliflozin:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 40.8 %  
Exposure time: 28 d

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
6.1	11.08.2025	595280-00021	Date of first issue: 04.04.2016

---

**Magnesium stearate:**

Biodegradability : Result: Not biodegradable  
Remarks: Based on data from similar materials

**Propyl 3,4,5-trihydroxybenzoate:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 49.4 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301F

**Bioaccumulative potential****Components:****Sitagliptin Phosphate:**

Partition coefficient: n-octanol/water : log Pow: -0.03

**Ertugliflozin:**

Partition coefficient: n-octanol/water : log Pow: 2.47

**Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: > 4

**Propyl 3,4,5-trihydroxybenzoate:**

Partition coefficient: n-octanol/water : log Pow: 1.8  
Remarks: Calculation

**Mobility in soil****Components:****Sitagliptin Phosphate:**

Distribution among environmental compartments : log Koc: 4.37

**Ertugliflozin:**

Distribution among environmental compartments : log Koc: 2.88

**Other adverse effects**

No data available

---

**Section 13: Disposal considerations****Disposal methods**

Waste from residues	: Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	: Empty containers should be taken to an approved waste han-

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
6.1	11.08.2025	595280-00021	Date of first issue: 04.04.2016

ding site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

**Section 14: Transport information****International Regulations****UNRTDG**

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Environmentally hazardous	:	no

**IATA-DGR**

UN/ID No.	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Packing instruction (cargo aircraft)	:	Not applicable
Packing instruction (passenger aircraft)	:	Not applicable

**IMDG-Code**

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
EmS Code	:	Not applicable
Marine pollutant	:	Not applicable

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**National Regulations****NZS 5433**

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Hazchem Code	:	Not applicable

**Special precautions for user**

Not applicable

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
6.1	11.08.2025	595280-00021	Date of first issue: 04.04.2016

**Section 15: Regulatory information****Safety, health and environmental regulations/legislation specific for the substance or mixture****HSNO Approval Number**

HSR100425 Pharmaceutical Active Ingredients Group Standard

Tolerable Exposure Limits (TEL)

Not applicable

Environmental Exposure Limits (EEL)

Not applicable

**HSW Controls**

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

**The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

**Section 16: Other information**

Revision Date : 11.08.2025

**Further information**Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

NZ OEL : New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

ACGIH / TWA : 8-hour, time-weighted average

NZ OEL / WES-TWA : Workplace Exposure Standard - Time Weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with

**Ertugliflozin (< 2%) / Sitagliptin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
6.1	11.08.2025	595280-00021	Date of first issue: 04.04.2016

---

x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN